233 South 10th Street
Suite 522
Philadelphia, PA 19107
(215) 503-7296
(215) 923-9248 fax
Suite 522
Philadelphia, PA 19107
(215) 503-7296
(215) 923-9248 fax
Most Recent Peer-reviewed Publications
- TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells
- SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor
- BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
- Resistance to Chemotherapy. Short-Term Drug Tolerance and Stem Cell-Like Subpopulations.
- Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells
- The Yin-Yang of RAF inhibitors
- ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity
- Meeting report from the 2011 international melanoma congress, Tampa, Florida
- Axl of evil
- Finding the root of the problem: the quest to identify melanoma stem cells.
- Mechanisms of resistance to RAF inhibitors in melanoma
- FOXD3 regulates migration properties and Rnd3 expression in melanoma cells
- Mind the BAP
- Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
- Paying particle attention to novel melanoma treatment strategies
- The wrath of RAFs: Rogue behavior of B-RAF kinase inhibitors
- CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway
- Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells
- αB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells
- FOXD3 is a mutant B-RAF-regulated inhibitor of G1-S progression in melanoma cells